# amyris

#### AMYRIS, INC.

First Quarter 2021 Earnings Conference Call

May 6, 2021 – 6:00 am PT





#### **Forward-Looking Statements**

This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding 2021 financial guidance and outlook, goals and strategic priorities; and Amyris's expectations regarding its development pipeline, planned product launches new markets and industries; and other future milestones such as the completion of its new Brazil plant, pending and future strategic transactions, planned investments, expansion into other markets and industries, and the timing thereof. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, regulatory approval, production, launch and commercialization of products and brands, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

#### NON-GAAP FINANCIAL INFORMATION

To supplement Amyris's financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), Amyris uses non-GAAP financial measures that Amyris believes are helpful in understanding our financial results. These non-GAAP financial measures are among the factors management uses in planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris's historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures, when considered together with financial information prepared in accordance with GAAP, can enhance investors' and analysts' abilities to meaningfully compare our results from period to period, identify operating trends in our business, and track and model our financial performance. In addition, management believes that these non-GAAP financial measures allow for greater transparency into the indicators used by management to understand and evaluate Amyris's business and make operating decisions. Non-GAAP financial information is not prepared under a comprehensive set of accounting rules, and therefore, should only be read in conjunction with financial information reported under GAAP in order to understand Amyris's operating performance. A reconciliation of the non-GAAP financial measures in this presentation to the most directly comparable GAAP financial measure, is provided in the tables attached to this presentation.

Totals in this presentation may not foot due to rounding.

Q1 2021 Earnings Conference Call | May 6, 2021

# Agenda

- 1 Executive Overview
- 2 Operational Review
- 3 Financial Review

4 Q&A



John Melo President and Chief Executive Officer



Han Kieftenbeld Chief Financial Officer





Eduardo Alvarez Chief Operating Officer

# **Record Growth and Strong Liquidity**

Enhanced capital structure, solidified liquidity and financial flexibility to accelerate growth

- Continued strong revenue growth from product portfolio
- Well-positioned development pipeline to deliver new ingredients at scale
- Completed three strategic transactions evidencing value of our technology. Expect \$270m in future earnouts and milestone payments
- Reduced debt from \$297m at start of 2020 to \$115m at end of Q1 2021 of which \$60m is convertible to equity (i.e. net \$55m)
- Current cash balance \$235m





amvris | Page 4

### Synthetic Biology is Capable of Remaking Most of the World's Chemistry

Global chemicals market was \$4 trillion in 2019<sup>1</sup>



Intermediary chemicals serve as building blocks for most consumer products

Traditionally, molecules are either plant or animal-derived or petrochemical-based



Consumers want companies to replace their hydrocarbonbased products with ones that are more environmentally friendly and sustainable

Synthetic Biology is capable of remaking most of the world's chemistry

It is better for the planet, better for people and also becoming better for profits



At Amyris, we successfully develop, scale and commercialize


We are a platform company that leads the sector with science that designs solutions with the end in mind



We work with partners to identify the market opportunity, drive adoption, and determine what attributes make a real difference in formulation

<sup>1</sup> Source: Statista (2021). 2019 revenue was \$3.94 trillion. Report: Total revenue of the global chemical industry from 2005 to 2019.

## **Building Blocks: Evolving Our Consumer Brands Portfolio**



NO.

# ROSE INC

**BEAUTY WITH SUBSTANCE** 




ROSE INC

SEIGHTEN SERUS (CLASSCIE SERUS

ROSE INC.

#### amyris | Page 7

# **Building Blocks: Evolving Our Ingredients Portfolio**



# Partnership to Drive Growth of Sugar Reduction and Fermentation-based Food Ingredients

- Expanded global reach, adoption of Amyris's sugar reduction technology, including fermented Reb M, with Ingredion commercial partnership
- R&D collaboration to create nature-based sweeteners and other fermentation-based food ingredients from Amyris proprietary Lab-to-Market technology platform
- Shared investment and profitability in ingredient production and commercialization





Proprietary Lab-to-Market operating system with sector-leading commercial success record in synthetic biology and clean manufacturing



Global market reach, formulation capabilities and commercial teams with broad offering of sugar reduction solutions









# **Q1 2021 Operations Update**

Accelerating momentum and delivering industry-leading biomanufacturing performance



#### **Q1 2021 Financial Highlights**

Record revenue and significantly positive adjusted EBITDA

- Record Sales revenue of \$177m, included \$144m flavor and fragrance strategic transaction
- **Product revenue** of \$28m was up **47%** YoY, with Consumer revenue up 73% YoY and Ingredient revenue +25% YoY
- Gross margin of 91% improved from 63% in PY and increased \$142m YoY with \$138m from strategic and one-off items. Underlying Gross Margin at 52%, up \$4m YoY, compared to 56% PY due primarily to ingredient product mix
- **Cash operating expense** of \$54m increased \$9m or **21%** YoY, mostly due to marketing investments in consumer brands and new R&D programs. G&A decreased 3% YoY
- Adjusted EBITDA was \$103m, a \$130m YoY improvement due to strategic transaction, higher underlying revenue, and improved product margin, partially offset by higher operating expense
- Debt at end of Q1 2021 of \$115m compares to \$209m at end of Q1 2020. Interest Expense of \$6m was down \$9m or 61% from PY


+507% TOTAL REVENUE

91% GROSS MARGIN (NON-GAAP)

\$103m ADJUSTED EBITDA

\$94m Yoy reduction in debt

#### Q1 2021 Sales Revenue By Category




Consumer & Ingredients (\$m) excl one-offs
 Collaboration & Grants (\$m) excl one-offs

Sales Revenue	Q1 2021						
\$m	2021	2021 2020 YoY%					
Consumer	15.7	9.1	73%				
Ingredients <sup>1</sup>	12.7	10.2	25%				
Underlying Product <sup>1</sup>	28.4	19.3	47%				
Collaboration <sup>2</sup>	4.9	5.0	-3%				
Underlying Total <sup>3</sup>	33.3	24.3	37%				
One-off	143.6	4.8	2882%				
Reported Total	176.9	29.1	507%				

<sup>1</sup> Excl one-off (Vitamin E & DSM strategic transaction) <sup>2</sup> Excl one-off (Vitamins in 2020)

<sup>3</sup> Excl one-off (Vitamins & DSM strategic Transaction)

#### **Q1 2021 Key Financials**




© 2021 Amyris, Inc. All Rights Reserved.


#### amyris | Page 13

#### **2021 Full Year Outlook**

- Underlying total revenue (Product, Collaboration & Grants) expected to be in the \$250m range.
  Reported total revenue expected to be around \$400m inclusive of strategic transactions
- Continued growth combined with strategic transactions expected to result in positive full year adjusted EBITDA
- **Debt** expected to be **below \$100m** by year-end

#### **A Winning Business Model and Advantaged Portfolio**







\*2021 launch dates are anticipated launch dates

Our proprietary Lab-to-Market operating system has delivered predictable commercialization, significant cost reduction and fast time-to-market

© 2021 Amyris, Inc. All Rights Reserved.

Our Ingredients Pipeline has delivered unique, natural, sustainably sourced, platform molecules that disrupt markets and enable the ESG agenda of industry leaders Our **Consumer Brands** have delivered on the No Compromise<sup>®</sup> promise for health, clean beauty and personal care products that make people and our planet healthier **amyris** | Page 15

#### We Deliver on The Promise of Synthetic Biology

- Leading Synthetic Biology platform: fast, cost-effective and sustainable approach using innovative and disruptive chemistry to commercialize products
- **Delivering industry-leading growth:** in fast-growing and attractive Health, Beauty and Wellness markets driven by consumer preferences for clean, safe and sustainable
- Investing in the future: balancing continued growth and optimization of portfolio with new science-driven opportunities to make our planet healthier
- Long-term approach to shareholder value: establishing the foundation for profitable growth, cash delivery and self-funding












#### **Q1 2021 Debt and Other Items**

Item \$m	3/31/2021	3/31/2020	Comment
Debt	115	209	Debt has been reduced by 45%
Cash	144	3	Driven by strategic transaction income
Net Debt	(29)	206	Significant improvement in both debt and cash

Item \$m	Q1 2021	Q1 2020	Comment
Net interest expense	6	15	Down 60% due to lower average debt position versus prior year and lower average interest rate
Effective tax rate			Not calculated due to negative income
Capital expenditures	3	1	No issues to note



	03/31/20	06/30/20	09/30/20	12/31/20	03/31/21
Common outstanding	163.9m	204.6m	239.2m	245.0m	273.3m
Fully diluted shares	252.1m	278.8m	336.0m	336.0m	332.8
Market capitalization	\$420m	\$874m	\$698m	\$1,514m	\$5,219m
Total capitalization	\$629m	\$1,051m	\$873m	\$1,684m	\$5,334m

# **GAAP to Non-GAAP Reconciliations**

#### Sales Revenue Breakdown

	1	Fhree Mon Marcl		ded	
(In millions)	2	2021	2	2020	
Revenue:					
Renewable products	\$	28.2	\$	17.9	
Licenses and royalties	\$	143.8	\$	5.2	
Grants and collaborations	\$	4.9	\$	6.1	
Total revenue	\$	176.9	\$	29.1	
		Thre	e Mon Marcl	ths Ended h 31,	
		Thre			
(In millions)	2	2021	Marc	h 31, 2020	YoY%
Consumer	2	2 <b>021</b> 15.7	Marc	<b>h 31,</b> 2020 9.1	73%
	2	2021	Marc	h 31, 2020	73%
Consumer	2	2 <b>021</b> 15.7	Marc	<b>h 31,</b> 2020 9.1	
Consumer Ingredients		2021 15.7 12.7	Marc	h 31, 2020 9.1 10.2	73% 25% <b>47%</b>
Consumer Ingredients <b>Product</b> Collaborations & Grants		2021 15.7 12.7 28.4	Marc	h 31, 2020 9.1 10.2 19.3	73% 25% <b>47%</b> -3%
Consumer Ingredients <b>Product</b>	2	2021 15.7 12.7 28.4 4.9	Marc	h 31, 2020 9.1 10.2 19.3 5.0	73% 25%

<sup>1</sup> Incl one-off DSM transaction

#### GAAP to Non-GAAP Gross Profit and Gross Margin

		Three Months Ended March 31,					
<u>(In thousands)</u>		2021		2020			
Revenue (GAAP and non-GAAP)	\$	176,859	\$	29,130			
Cost of products sold (GAAP)	\$	22,659	\$	11,790			
Other costs/provisions		(4,473)		(1,431)			
Manufacturing capacity fee adjustment		(1,482)		-			
Inventory lower-of-cost-or-net realizable value adjustment		161		616			
Excess capacity		(205)		(66)			
Stock-based compensation expense		(63)		-			
Depreciation and amortization		(514)		(233)			
Cost of products sold (non-GAAP)	\$	16,083	\$	10,676			
Adjusted gross profit (non-GAAP)	\$	160,776	\$	18,454			
Gross margin %		91%		63%			

# **GAAP to Non-GAAP Reconciliations**

#### GAAP to Non-GAAP Net Income (Loss) and EPS

#### GAAP to Non-GAAP Operating Expense

		Three Months Ended March 31,					
(In thousands)		2021		2020			
Research and development expense (GAAP)	\$	23,332	\$	17,126			
Stock-based compensation expense		(1,062)		(1,065)			
Depreciation and amortization		(1,321)		(1,225)			
R&D performance agreement termination		(1,850)		-			
Research and development expense (non-GAAP)	\$	19,099	\$	14,836			
Sales, general and administrative expense (GAAP)	\$	37,922	\$	32,014			
Stock-based compensation expense		(3,156)		(2,439)			
Depreciation and amortization		(279)		(261)			
Sales, general and administrative expense (non-GAAP)	\$	34,487	\$	29,314			
Cash operating expense	\$	53,586	\$	44,150			
Cash operating expense	ψ	55,580	φ	74,12			

	Thr	ee Months	End	led March 31
(In thousands, except per share data)		2021		2020
Net loss attributable to Amyris, Inc. common stockholders - Basic (GAAP)	\$	(289,152)	\$	(86,757
Non-GAAP adjustments:				
Stock-based compensation expense		4,281		3,504
(Gain) loss from change in fair value of derivative instruments		22,745		(3,282
Loss from change in fair value of debt		326,785		16,50
Loss upon extinguishment of debt		27,313		27,31
Income attributable to noncontrolling interest		1,200		
Loss allocated to participating securities		(2,099)		(1,08)
Inventory lower-of-cost-or-net realizable value adjustment		(161)		(616
R&D Performance Agreement termination		1,850		
Manufacturing capacity fee adjustment		1,482		
Other (income) expense, net, and (gain) loss from investment in affiliate		286		41
Adjusted net income (loss) attributable to Amyris, Inc. common stockholders (non-GAAP)	\$	94,530	\$	(44,00
Weighted-average shares outstanding				
Weighted-average shares of common stock outstanding used in computing earnings (loss) per share attributable to				
Amyris, Inc. common stockholders (non-GAAP)	26	7,733,555		155,065,63
Loss per share attributable to Amyris, Inc. common stockholders - Basic (GAAP)	\$	(1.08)	\$	(0.5
Non-GAAP adjustments:				
Stock-based compensation expense		0.02		0.0
(Gain) loss from change in fair value of derivative instruments		0.08		(0.0)
Loss from change in fair value of debt		1.22		0.1
Loss upon extinguishment of debt		0.10		0.1
Income attributable to noncontrolling interest		0.00		-
Loss allocated to participating securities		(0.01)		(0.0)
Inventory lower-of-cost-or-net realizable value adjustment		(0.00)		(0.0)
R&D Performance Agreement termination		0.01		-
Manufacturing capacity fee adjustment		0.01		-
Other (income) expense, net, and (gain) loss from investment in affiliate		0.00		0.0
Adjusted earnings (loss) per share attributable to Amyris, Inc. common stockholders (non-GAAP) <sup>(1)</sup>	\$	0.35	\$	(0.2
<sup>(1)</sup> Amounts may not sum due to rounding.		_		_

# **GAAP to Non-GAAP Reconciliations**

#### GAAP to Non-GAAP Net Income (Loss) to EBITDA and Adjusted EBITDA

		Three Months E	March 31,		
(In thousands)		2021	2020		
Net loss attributable to Amyris, Inc. common stockholders, basic	\$	(289,152)	\$	(86,757)	
Adjustment to earnings and Loss allocated to participating securities	\$	(2,099)	\$	(1,087)	
Dividend to preferred stockholder on issuance and modification of common stock warrants	\$	-	\$	-	
Dividend to preferred stockholders on conversion of preferred stock	\$	-	\$	-	
Interest Exp, Income Tax, Depreciation/Amortization	\$	5,813	\$	15,002	
Income Tax	\$	55	\$	91	
Depreciation & Amortization	\$	2,114	\$	1,719	
EBITDA	\$	(283,269)	\$	(71,032)	
Interest & Other income (expense), net	\$	354,384	\$	44,233	
Gain (loss) from change in fair value of derivative instruments	\$	22,745	\$	(3,282)	
Income attributable to noncontrolling interest	\$	1,200	\$	-	
Lower Cost to Market Adjustment	\$	(161)	\$	(616)	
R&D Performance Agreement termination	\$	1,850	\$	-	
Manufacturing capacity fee adjustment	\$	1,482			
Stock Compensation	\$	4,281	\$	3,504	
Adjusted EBITDA	\$	102,512	\$	(27,193)	